MyFinsight
Home
Blog
About
ADC Therapeutics SA (ADCT)
ADC Therapeutics SA (ADCT)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$11,906K
Free Cash flow
-$11,807K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Accounts payable
Accretion expense of deferred ro...
Share-based compensation expense
Others
Negative Cash Flow Breakdown
Warrant obligations, decrease in...
Cumulative catch-up adjustment, ...
Inventory
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-16,565
-32,968
-6,409
-40,966
Share-based compensation expense
4,550
2,442
673
2,000
Accretion expense of deferred royalty obligation
7,364
6,839
7,784
7,400
Cumulative catch-up adjustment, deferred royalty obligation
-6,401
-
22,729
-321
Impairment of long-lived assets and prepaid expenses
0
-
-545
7,240
Write-downs of inventory
171
1,473
411
237
Depreciation
-
-
0
1
Amortization of operating lease right-of-use assets
-
114
113
121
Share of results in joint venture
-
-
0
0
Warrant obligations, decrease in fair value
-14,367
-2,227
-
-
Amortization of debt discount, senior secured term loan
940
225
246
733
Other
-281
603
122
53
Accounts receivable, net
-3,010
1,928
6,187
-3,266
Inventory
3,292
-16
853
516
Prepaid expenses and other current assets
-249
-2,007
215
1,602
Other long-term assets
0
-
0
-100
Accounts payable
7,469
-3,874
932
-1,290
Accrued expenses and other current liabilities
3,818
-3,183
1,974
-799
Operating lease liabilities
-111
-247
-510
-992
Other long-term liabilities
1,191
2,204
-6,720
2,225
Net cash used in operating activities
-11,807
-29,710
-31,123
-29,630
Payment for purchases of property and equipment
0
32
0
0
Proceeds from the sale of equipment
-
-
-659
-
Net cash used in investing activities
0
-32
659
0
Proceeds from the sale of common shares, net of transaction costs
0
-20
43,522
-479
Proceeds from pre-funded warrants, net of transaction costs
0
-
14,612
0
Proceeds from share issuance under stock purchase plan
0
0
0
0
Proceeds from the exercise of stock options
118
205
219
281
Taxes paid related to net settled equity awards
217
768
1,264
0
Net cash (used in)/ provided by financing activities
-99
-583
57,089
-198
Net increase (decrease) in cash and cash equivalents
-11,906
-30,325
26,625
-29,828
Exchange (losses)/gains on cash and cash equivalents
5
-5
-25
330
Cash and cash equivalents at beginning of period
231,008
261,338
234,738
250,867
Cash and cash equivalents at end of period
219,107
231,008
261,338
234,738
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Net increase
(decrease) in cash and cash...
-$11,906K
(-189.06%↓ Y/Y)
Accounts payable
$7,469K
(186.05%↑ Y/Y)
Accretion expense of
deferred royalty...
$7,364K
(-47.20%↓ Y/Y)
Share-based compensation
expense
$4,550K
(7.51%↑ Y/Y)
Accrued expenses and
other current...
$3,818K
(144.42%↑ Y/Y)
Accounts receivable, net
-$3,010K
(-151.30%↓ Y/Y)
Other long-term
liabilities
$1,191K
(-70.84%↓ Y/Y)
Amortization of debt
discount, senior secured...
$940K
(11.77%↑ Y/Y)
Other
-$281K
(41.34%↑ Y/Y)
Prepaid expenses and
other current assets
-$249K
(96.47%↑ Y/Y)
Write-downs of inventory
$171K
(-89.55%↓ Y/Y)
Proceeds from the
exercise of stock options
$118K
(247.06%↑ Y/Y)
Net cash used in
operating activities
-$11,807K
(85.32%↑ Y/Y)
Net cash (used in)/
provided by financing...
-$99K
(-100.11%↓ Y/Y)
Canceled cashflow
$29,043K
Canceled cashflow
$118K
Net loss
-$16,565K
(82.61%↑ Y/Y)
Taxes paid related to
net settled equity...
$217K
(-13.20%↓ Y/Y)
Warrant obligations,
decrease in fair value
-$14,367K
Cumulative catch-up
adjustment, deferred...
-$6,401K
(-3165.82%↓ Y/Y)
Inventory
$3,292K
(225.30%↑ Y/Y)
Operating lease
liabilities
-$111K
(88.92%↑ Y/Y)
Buy us a coffee